This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

A pilot study using nabilone for symptomatic treatment in Huntington’s disease


Curtis, Adrienne, Mitchell, Ian, Patel, Smitaa, Ives, Natalie, Rickards, Hugh


Movement Disorders: Official Journal Of The Movement Disorder Society, Volume: 24, No.: 15, Pages.: 2254-2259

Year of Publication



Pilot study of nabilone in Huntington’s disease (HD). Double-blind, placebo-controlled, cross-over study of nabilone versus placebo. Primary outcome, Unified Huntington’s Disease Rating Scale (UHDRS) total motor score. Secondary measures: UHDRS subsections for chorea, cognition and behavior, and neuropsychiatric inventory (NPI). 44 randomized patients received either nabilone (1 or 2 mg) followed by placebo (n = 22), or placebo followed by nabilone (n = 22). Recruiting was straightforward. Nabilone safe and well tolerated, no psychotic episodes. Assessment of either dose of nabilone versus placebo showed a treatment difference of 0.86 (95% CI: -1.8 to 3.52) for total motor score; 1.68 (95% CI: 0.44 to 2.92) for chorea; 3.57 (95% CI: -3.41 to 10.55) for UHDRS cognition; 4.01 (95% CI: -0.11 to 8.13) for UHDRS behavior, and 6.43 (95% CI: 0.2 to 12.66) for the NPI. Larger longer RCT of nabilone in HD is feasible and warranted.;

Bibtex Citation

@article{Curtis_2009, doi = {10.1002/mds.22809}, url = {}, year = 2009, month = {nov}, publisher = {Wiley-Blackwell}, volume = {24}, number = {15}, pages = {2254--2259}, author = {Adrienne Curtis and Ian Mitchell and Smitaa Patel and Natalie Ives and Hugh Rickards}, title = {A pilot study using nabilone for symptomatic treatment in Huntington{textquotesingle}s disease}, journal = {Movement Disorders} }


adult, aged, analogs derivatives, antianxiety agents, behavioral symptoms, cognition disorders, complications, disability evaluation, double-blind method, dronabinol, drug therapy, etiology, female, humans, huntington disease, male, middle aged, nabilone, neuropsychological tests, outcome assessment (health care), pilot projects, therapeutic use

Countries of Study


Types of Dementia


Types of Study

Randomised Controlled Trial

Type of Outcomes

Behaviour, Cognition, Physical Health

Type of Interventions

Pharmaceutical Interventions

Pharmaceutical Interventions